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Abstract
In this research, we developed a novel chimeric HTNV-IL-2-G2 DNA vaccine plasmid by genetically
linking IL-2 gene to the G2 segment DNA and tested whether it could be a candidate vaccine.
Chimeric gene was first expressed in eukaryotic expression system pcDNA3.1 (+). The HTNV-IL-
2-G2 expressed a 72 kDa fusion protein in COS-7 cells. Meanwhile, the fusion protein kept the
activity of its parental proteins. Furthermore, BALB/c mice were vaccinated by the chimeric gene.
ELISA, cell microculture neutralization test in vitro were used to detect the humoral immune
response in immunized BALB/c mice. Lymphocyte proliferation assay was used to detect the
cellular immune response.- The results showed that the chimeric gene could simultaneously evoke
specific antibody against G2 glycoprotein and IL-2. And the immunized mice of every group elicited
neutralizing antibodies with different titers. Lymphocyte proliferation assay results showed that the
stimulation indexes of splenocytes of chimeric gene to G2 and IL-2 were significantly higher than
that of other groups. Our results suggest that IL-2-based HTNV G2 DNA can induce both humoral
and cellular immune response specific for HTNV G2 and can be a candidate DNA vaccine for
HTNV infection.
Introduction
The Hantaan virus (HTNV) is a member of the genus
Hantavirus of the family Bunyaviridae and a causative
agent of hemorrhagic fever with renal syndrome (HFRS)
[1,2]. More than 100,000 cases of HFRS are reported
annually, with a mortality rate between 2% and 10% [3].
However, no effective vaccine has been developed to pre-
vent this disease.
HTNV is a spherical, enveloped virus with a genome con-
sisting of three segments of single-stranded, negative-
sense RNA. The three segments are designated as large (L),
medium (M), and small (S) segments that encode RNA-
dependent RNA polymerase, respectively [4]]. It is indi-
cated that the glycoprotein (GP), which was encoded by
M segment, could elicit organism to produce neutralizing
antibody and could protect infected animal and human
Published: 22 October 2008
Genetic Vaccines and Therapy 2008, 6:15 doi:10.1186/1479-0556-6-15
Received: 29 May 2008
Accepted: 22 October 2008
This article is available from: http://www.gvt-journal.com/content/6/1/15
© 2008 Hao et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Genetic Vaccines and Therapy 2008, 6:15 http://www.gvt-journal.com/content/6/1/15
Page 2 of 9
(page number not for citation purposes)
body from Hantavirus lethal infection [5]. Moreover, the
neutralization sites of GP mainly exist in G2 [6].
In the past few years, immunization with naked DNA has
become an alternative approach for vaccination against
infectious diseases. The expression vectors used for DNA
vaccines usually contain the gene(s) for an antigenic por-
tion of a virus or bacteria, under the transcriptional con-
trol of a mammalian promoter. Direct injection of the
DNA into skeletal muscles results in the synthesis of pro-
teins that subsequently stimulate the host immune system
leading to both humoral and cellular immune responses
specific to the expressed protein [7,8]. Recently, several
published reports describe the application of DNA vac-
cines to examine the protective potential of several HTNV
proteins [9-11]. We have previously reported that the G2
glycoprotein gene could be expressed in cells transiently
and retain specific antigenicity to the Chinese Hantavirus
strain H8205 (from the Epidemic Disease Research Insti-
tute, Academy of Military Medical Sciences, China), indi-
cating that the HTNV-G2 recombinant plasmid could be
used to develope DNA vaccine against Hantavirus [12].
Use of cytokines as adjutants can enhance various
immune responses when administered during the devel-
opment of an immune response to a particular antigen.
IL-2 is one of the extensively studied cytokine adjuvants
[13-15]. When administered in multiple injections, IL-2
increased the development of antigen-specific immune
response and protective immunity against challenge with
the infectious agents [16]. The adjuvant efficacy was fur-
ther enhanced by physically linking IL-2 to an antigen so
that the cytokine effect is retained in the local environ-
ment where the immune response is initiated. Previous
studies have shown that co-expression of IL-2 has also
been shown to enhance the immune response to the
HSV1 glycoprotein D antigen in DNA vaccines [17]. These
investigations have made IL-2 an attractive adjuvant for
vaccine development.
In this study, we developed a HTNV-G2 and IL-2 fusion
transgene that directly elicited specific anti-HTNV
humoral and cellular immune response. These results sug-
gest that HTNV-IL-2-G2 DNA may be used as a candidate
vaccine.
Methods
Mice, viruses, and cells
C57BL/6 mice aged 6–8 weeks- (The Laboratory Animal
Center, Tongji Medical College, Huazhong University of
Science and Technology, Wuhan, China) were housed in
microisolated, pathogen-free facility. All experiments
were carried out in accordance with the National Institute
of Health Guide for the Care and Use of Laboratory Ani-
mals (NIH Publications No. 80-23, revised 1978). All
efforts were made to minimize animal suffering, reduce
the number of animals used, and utilize alternatives to in
vivo techniques, when available. HTNV strains H8205
(Epidemic disease Research Institute, Academy of military
medical sciences, China) were propagated in Vero E6 cells
(VeroE6, GDC015, China Center for Type Culture Collec-
tion, China). Transient expression experiments were per-
formed with COS-7 cells (COS-7, GDC054, China Center
for Type Culture Collection, China). All cell types were
maintained in Dulbecco's modified Eagle's medium
(DMEM) (Invitrogen™ Life Technologies)supplemented
with 10% fetal calf serum (FCS).
Construction of vaccine plasmids
To construct the eukaryotic expression plasmid DNA vec-
tor for IL-2 DNA, the full-length IL-2 DNA was amplified
from plasmid PUC19-IL-2 (Department of molecular
biology, Tongji Medical College, Huazhong University of
Science and Technology, Wuhan, China) encoding
human IL-2 gene by PCR using IL-2 primers (forward, 5'-
GGCATCGCAAGCTTATGGCACCTACTTCAA-3'reverse,
5'- GCTCTCCGGTACCCTGCAGTGTTGAGATGA -3'),
which also introduced an Hind III and KpnIrestriction
sites, respectively (underlined) to the amplicons. The
PCR-amplified IL-2 DNA fragments were digested with
restriction endonucleases Hind III and KpnI and annealed
by ligation with T4 DNA ligase (TaKaRa, Japan) to Hind
III and KpnI-digested pcDNA3.1 (+) expression vector
(Invitrogen™ Life Technologies) DNA, downstream of the
CMV promoter, hereafter referred to as pcDNA3.1/IL-2.
To construct the DNA vector containing the fused form of
HTNV IL-2-G2, HTNV G2 DNA was amplified from plas-
mid pcDNA3.1/HTNV-G2 (Department of Pathogenic
Biology, Tongji Medical College, Huazhong University of
Science and Technology, Wuhan, China) encoding G2
gene by PCR using primers(forward, 5'- GGGGTAC-
CTACGGGCTGCAAGTGCTTCTGAAAC -3'reverse, 5'-
CCGCTCGAGTAGGACTATGCCTTCTTGTGC -3')
designed to introduce KpnI and XhIrestriction sites at
5'and 3'ends of the amplicons, respectively(underlined),
and subcloned into pcDNA3.1/IL-2 at the KpnI restriction
site's 3'-flank to the IL-2 gene, resulting in pcDNA3.1/
HTNV-IL-2-G2. Following ligation, the reconstruct plas-
mids were introduced into transformation-competent E.
coli DH5α (TaKaRa, Japan) and cultured overnight. Plas-
mid DNA was purified by using Qiagen Maxiprep DNA
purification kits(Qiagen, San Diego, CA) according to the
manufacturer's directions. The presence of the inserted
DNA fragment was confirmed by restriction enzyme
digestion and gel electrophoresis. All the constructs were
further verified by DNA-sequencing (Applied Biosystems,
USA). The DNA was finally resuspended in phosphate-
buffered saline (PBS) at a concentration of 1 mg/ml.Genetic Vaccines and Therapy 2008, 6:15 http://www.gvt-journal.com/content/6/1/15
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Cell culture and transfection
COS-7 cells were grown in DMEM medium supplemented
with 10% calf serum. Lipofectamine™ 2000 reagent (Inv-
itrogen™ Life Technologies) was used in transfection. The
transfection was performed according to the protocol of
Invitrogen. COS-7 cells were transfected with pcDNA3.1/
HTNV IL-2-G2 and the control group pcDNA3.1(+). After
48–72 h, the expressed proteins were detected.
Immunofluorescence
For immunofluorescence, the transfected COS-7 cells
were fixed in PBS containing 4% paraformaldehyde for 15
min at RT, followed by extensive washing with PBS. After
blocking in PBS containing 3% bovine serum albumin
(BSA) for 1 h, the cells were incubated with anti-G2 Mab
(Epidemic disease Research Institute, Academy of military
medical sciences, China) or polyclonal mouse anti-IL2
antibody (Santa Cruz, CA, USA, at 1:50 dilution) for 1 h
at RT, bridged by avidin-conjugated anti-mouse IgG
(Santa Cruz, CA, USA, at 1:300 dilution) for 1 h at RT,
subsequently detected with FITC-labeled goat anti-mouse
IgG (Santa Cruz, CA, USA, at 1:32 dilution) and rodamin-
labeled biotin (Santa Cruz, CA, USA, at 1:100 dilution)
for 1 h at RT. After thoroughly washing, the coverslips
were mounted and observed with a confocal fluorescence
microscope
Western blot analysis
To detect protein expression by western blot, the trans-
fected cells were lysed with lysis buffer. The cell lysates
were run on sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE), and then transferred electro-
phoretically to a nitrocellulose membrane. The mem-
branes were incubated with monoclonal antibody (MAb)
against IL-2 (Santa Cruz, CA, USA, at 1:50 dilution) or
against HTNV G2 (at 1:400 dilution), detected by horse-
radish peroxidase (HRP)-conjugated goat anti-mouse IgG
(at 1:600 dilution, Santa Cruz, CA, USA), and developed
using a chemiluminescent substrate (Pierce, Rockford, IL,
USA). The emitted light was captured on X-ray film.
Recombinant protein production
The cells cultured at 37°C in a shaking incubator over-
night. When the optical density at 600 nm (OD600)
reached 0.4–0.6, a final concentration of 0.3 mM of IPTG
was added to the culture to induce the protein expression,
and the cells were grown for another 5 h. The cultures
were harvested by centrifugation in 50 ml volumes at
5000 × g for 5 min at 4°C, disrupted by sonication in a
lysis buffer containing nonionic detergent and lysozyme.
IL-2-G2 proteins were purified using nickel nitriloacetic
acid (Ni-NTA)-agarose column (Qiagen, Valencia, CA,
USA) as recommended by the manufacturer. The identity
of the purified protein was verified by western blot with
anti-IL-2 MAb or anti-G2 MAb.
DNA vaccination of C57BL/6 mice
C57BL/6 mice were immunized with DNA constructs,
using a modification of a previously described method
[18]. Briefly, mice, three to four per group, five groups in
total, were immunized with 100 μg of pcDNA3.1/HTNV-
IL-2, pcDNA3.1/HTNV-G2, pcDNA3.1/HTNV-IL-2-G2,
pcDNA3.1 (+) plasmids (in 50 μl of PBS) and PBS respec-
tively, per mouse in both anterior tibial muscles that had
been pretreated with 0.25% bupivacaine 2 days before
vaccination. The second immunizations were given at
intervals of approximately 2 weeks using the same
amount of DNA, followed by boost once with 200 pM per
mouse of their homologous recombinant proteins 2
weeks after the second DNA immunization.
Detection of serum HTNV G2 and IL-2 specific antibodies
Sera were collected from a retroorbital plexus puncture 10
days after last protein boost or an animal's tail vein punc-
ture of immunized mice at weeks 0, 2, 4, 6, 8, 10, 12, 14
and 16 (where 0 represents the first day of immuniza-
tion). The G2 and IL-2-specific antibodies in the sera were
determined by an indirect ELISA method. The purified G2
of HTNV and IL-2 protein(Epidemic disease Research
Institute, Academy of military medical sciences, China)
were used as coating antigen. Then the sera were serially
diluted and reacted with G2 and IL-2 antigen. HRP-SPA
conjugate was used as secondary antibody. The titers were
defined as the reciprocal of the positive highest serum
dilution.
Cell microculture neutralization test
This test was performed on Vero E6 cell monolayers in 96-
well tissue culture plates with HTNV strains H8205. The
E6 clone of Vero cells was grown in DMEM medium sup-
plemented with 10% calf serum. The sera titer were two-
fold serially diluted from 1:15 in DMEM medium
containing 2% fetal calf serum and filtrated through 0.22
μm filter. Then it were incubated with viruses at 37°C for
90 min. Virus-sera mixtures were applied to cell monolay-
ers and incubated at 37°C for 8–10 days in 5% CO2 incu-
bator. Thereafter, the cells were lysed with three
consecutive freeze-thaw cycles. HTNV antigen in the lysate
was detected by sandwich ELISA. The anti-G2 Mab were
used as coating antibody and HRP-SPA conjugate were
used as secondary antibody.
Lymphocyte proliferation assay
Eight weeks after the final booster dose, mice were sacri-
ficed. Spleens were removed from immunized mice and
purified by lymphocytes separation medium. Then the
mice splenocytes suspension were applied in 96-well tis-
sue culture plates and co-incubated for 68 h with HTNV
G2 and IL-2 antigen, which was responsible for induction
of cellular response to HTNV, and blank control at 37°C
in 5% CO2 incubator. After applied MTT [(4,5-dimethyl-Genetic Vaccines and Therapy 2008, 6:15 http://www.gvt-journal.com/content/6/1/15
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thiazole-2-yl)-2,5-diphenyl tetrazolium-bromide,5 mg/
ml] 20 μL/well for 4 h, 150 μL/well DMSO was used to
dissolve the blue formazun precipitate. The extinction
coefficient was measured at 490 nm. The proliferation
index was calculated as follows: proliferation index =
A490 nm value stimulated with antigen/A490 nm value
stimulated with blank control.
Statistical analysis
Differences between assays are analyzed using one-tailed
or two-tailed pair t-test as appropriate (GraphPad Prism).
Probability values of  0.05 are considered to represent
significant differences.
Results
Construction and expression of vaccine plasmids in vitro
The eukaryotic expression plasmids, pcDNA3.1/HTNV-IL-
2-G2 were constructed as described in Fig. 1A. By restric-
tion analysis, a 0.8, 1.9 or 2.7 kb fragment was identified,
respectively, in HTNV IL-2-G2 recombinant plasmid (Fig.
1B), which corresponded, respectively, to IL-2, HTNV G2
or fused HTNV IL-2-G2 DNA. The nucleotide sequences
introduced into vectors were further confirmed by auto-
matic sequencing machine (Applied Biosystems, USA),
and matched human IL-2 (accession number
NM_000586) sequences deposited in the GenBank, per-
fectly (data not shown).
Expression of vaccine plasmids in vitro
We analysed the expressions of expected proteins by west-
ern blot. As shown in Fig. 2A, the immunoblots showed a
large protein band of about 72 kDa present in COS-7 cells
transfected with pcDNA3.1/HTNV-IL2-G2 that reacted
with both anti-IL2 and anti-G2 antibodies. This corre-
sponds to the expressed 72 kDa G2-IL2 fusion protein.
Immunofluorent staining revealed cytoplasmic expres-
sion of IL-2-G2 in COS-7 cells transfected with
pcDNA3.1/HTNV-IL-2-G2 (Fig. 2B). These results indi-
cated that the vaccine plasmidDNAs could express effi-
ciently in eukaryotic cells.
Genetic immunization results of vaccine plasmids
To investigate whether the recombinant DNA vectors
could elicit HTNV G2-specific humoral response, ELISA
and cell microculture neutralization test in vitro were used
to detect the humoral immune response in immunized
BALB/c mice. Meanwhile, the stimulation index of splen-
ocytes to G2 was measured by MTT assay.
ELISA results showed that the average titer of the specific
antibody against HTNV G2 in the mice immunized with
G2-IL2 was 1:70. Whereas, the specific antibody of the
average titer of pcDNA3.1/HTNV-IL-2-G2 group against
IL-2 was 1:100. The specific antibody of the average titer
of pcDNA3.1/HTNV-IL-2 group against HTNV G2 and IL-
2 were negative and 1:70. The results of pcDNA3.1/
HTNV-G2 group against HTNV G2 and IL-2 were 1:55 and
1:40. The results of pcDNA3.1 and PBS groups against
HTNV G2 and IL-2 were all negative (Fig. 3A).
Cell microculture neutralization test results showed that
part of the immunized mice of pcDNA3.1/HTNV-IL-2-G2
group could elicit neutralizing antibodies with different
titers. But the neutralizing antibody titers were low (Table
1).
Lymphocyte proliferation assay results showed that the
stimulation indexes of splenocytes of pcDNA3.1/HTNV-
IL-2-G2 group to IL-2 and G2 were all significantly higher
than that of other groups (Fig. 3B).
Discussion
It is well known that the G1 and G2 of HTNV may both
play important roles in evoking neutralizing antibody for
protecting against HTNV infection and in cell-mediated
protective immune response. Cytokines as indicators and
regulators of the immune network play important roles in
the immune and inflammatory responses. Previous stud-
ies showed the potential of the IL-2 gene as a molecular
adjuvant, which appear promising for protective immu-
nity against virus infection [19,20]. Meanwhile, augmen-
tation of DNA vaccine-elicited immune responses using
plasmid IL-2 has been reported in several murine disease
models [21,22].
In the present study, we developed a novel chimeric
HTNV IL2-G2 DNA vaccine by genetically linking IL2
gene to the full-length G2 segment DNA. Then we investi-
gated the expression of the recombinant vectors in mam-
malian cells. RT-PCR and western blot analysis results
proved by mRNA and protein levels that the recombinant
vector was transiently expressed in COS-7 cells-. The
immunofluorescence results showed that pcDNA3.1/
HTNV-IL-2-G2 DNA could express protein in mammal
cells.
Previous studies demonstrated that DNA vaccine plas-
mids expressing HTNV glycoproteins could elicit the pro-
duction of G2 protein in mice, hamsters and nonhuman
primates. In vaccinated hamsters, for example, the pres-
ence of G2 antigen correlated with protection against
HTNV infection [23]. On the basis of this work, BALB/c
mice were vaccinated with the recombinant eukaryotic
expression vector, pcDNA3.1/HTNV-G2-IL2. To avoid the
potential side effects associated with systemic administra-
tion of recombinant cytokines, such as the generation of
antibodies to IL2 and the neutralization of endogenous
IL2, a sustained but low level of cytokines delivered to tis-
sues of immune interactions may reduce the toxicity ofGenetic Vaccines and Therapy 2008, 6:15 http://www.gvt-journal.com/content/6/1/15
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Construction and expression of vaccine plasmids Figure 1
Construction and expression of vaccine plasmids. (A) A schematic representation of the recombinant vaccine plasmids. 
The plasmid pcDNA3.1/IL-2 was constructed by inserting the HindIII and an KpnIdigested the PCR-amplified IL-2 DNA frag-
ment into HindIII and an KpnI sites of pcDNA3.1 (+) between the cytomegalovirus promoter sequence and the bovine growth 
hormone polyadenylation sequence. The plasmid pcDNA3.1/HTNV-IL-2-G2 was constructed by inserting the KpnI and XhIdi-
gested HTNV G2 DNA fragment into the KpnI and EcoRI sites of pcDNA3.1/IL-2 plasmid upstream and in frame with the IL-2 
gene. (B) Identification of recombinant plasmids by using restriction enzyme digestion and agarose gel electrophoresis. Lane M, 
DNA molecular size marker; lanes1–3, pcDNA3.1/HTNV-IL-2-G2 digested with HindIII and KpnI, HindIII and XhI, KpnI and 
XhI, respectively.Genetic Vaccines and Therapy 2008, 6:15 http://www.gvt-journal.com/content/6/1/15
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Genetic immunization of vaccine plasmids Figure 2
Genetic immunization of vaccine plasmids. (A)Western blot analysis of protein expression of vaccine DNA in trans-
fected COS-7 cells. Lane 1 and 2, lysate of transfected COS-7 cells with pcDNA3.1/HTNV-IL-2-G2 were incubated with mouse 
anti-IL-2 and anti-G2 Mab, Lane 3 and 4, lysate of IL-2 and G2 protein with mouse anti-IL-2 antibody and mouse anti-G2 Mab, 
respectively. Lane 5 and 6, lysate of transfected COS-7 cells with pcDNA3.1(+)were incubated with mouse anti-IL-2 antibody 
and mouse anti-G2 Mab, respectively. M, molecular weight marker proteins: the mobility of size standards (in kDa) is shown to 
the left. (B) Indirect immunofluorescence of COS-7 cells transfected by recombinant vector pcDNA3.1/HTNV-IL-2-G2 (B-1) 
and pcDNA3.1(+) (B-2), incubated with mouse anti-G2 Mab, bridged by avidin-conjugated anti-goat IgG, and detected by 
rodamin conjugated biotin and FITC conjugated anti-mouse IgG, followed by laser confocal scanning.Genetic Vaccines and Therapy 2008, 6:15 http://www.gvt-journal.com/content/6/1/15
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these pleiotropic compounds, while improving their ther-
apeutic and practical value in providing vaccine adjuvant
effects. Direct injection into mouse skeletal muscle of
expression vector encoding cytokines provides such a
means. ELISA and cell microculture neutralization test in
vitro were used to detect the humoral immune response
in immunized BALB/c mice. The stimulation indexes of
splenocytes to IL2 and G2 were measured by lymphocyte
proliferation assay.- ELISA results showed that the chi-
meric gene could simultaneously elicit specific antibody
against IL-2 and G2.
Mice neutralizing antibodies protect mice and humans
from viral infection, it is very important to use a chimeric
vaccine such as the G2-IL2 that elicits a strong immune
response in vivo. Cell microculture test results showed
that the mice in the pcDNA3.1/HTNV-G2-IL2 vaccination
group produced different neutralizing antibody titers; but
they were all consistently low. This result may be caused
by variations in the expression level of genetic vaccines
that elicit low levels of antibody production
It has been demonstrated that both humoral and cellular
immune response were important in host defense against
HTNV [24]. Adoptive transfer of immune T cells protected
suckling mice from death following infection with HTNV
[25]. Furthermore, it was also found that T cells expressing
CD4-CD8+  markers on their surface were especially
important for elimination of infectious viruses in vivo
[25]. Others reported that T-cell-mediated immunity
plays an important role in resistance of mice to HTNV
infection. Recently, CTL epitopes in HTNV have been
identified [26]. MTT results showed that the stimulation
indexes of splenocytes of chimeric gene group to G2 and
IL-2 were significantly higher than that of control. The chi-
meric genes could also evoke cellular immune response in
mice.
In conclusion, the present results demonstrate that a DNA
vaccine that fuses IL2 with HTNV G2 can directly elicit a
specific anti-HTNV humoral and cellular immune
response in BALB/c mice. It was suggested that IL-2 and
HTNV G2-based HTNV DNA strategy appears to be an
attractive approach for the rational design and develop-
ment of new and more efficacious DNA vaccines for
HTNV-associated diseases.
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Antibody response in the sera of C57BL/6 mice immunized with different recombinant DNA vaccines Figure 3
Antibody response in the sera of C57BL/6 mice immunized with different recombinant DNA vaccines. C57BL/6 
mice were primed twice with pcDNA3.1/HTNV-IL-2, pcDNA3.1/HTNV-G2, pcDNA3.1/HTNV-IL-2-G2 and pcDNA3.1 (+) 
and PBS plasmids respectively. The second immunizations were given at intervals of approximately 2 weeks using the same 
amount of DNA. A) ELISA results of average titers of immunized mice sera. B) Analysis of the stimulation index of splenocytes 
of immunized mice to HTNV G2 and IL-2. All data were obtained from three independent experiments. Error bars represent 
means ± SEM. Significantly different from the corresponding control and vector. (**P < 0.01, vs pcDNA3.1(+). ##P < 0.01, vs 
PBS group).Genetic Vaccines and Therapy 2008, 6:15 http://www.gvt-journal.com/content/6/1/15
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